Zoledronic acid in combination with serine/threonine phosphatase inhibitors induces enhanced cytotoxicity and apoptosis in hormone-refractory prostate cancer cell lines by decreasing the activities of PP1 and PP2A: PHOSPHATASE INHIBITORS ENHANCES ZOLEDRONIC ACID CYTOTOXICITY